OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM

Authors

  • Mirmeera Girish Niharika Avanthi Institute of Pharmaceutical Sciences, JNTUH, Hyderabad, Telangana, India
  • Kannan Krishnamoorthy Department of Pharmacy, Annamalai University, Annamalai nagar, Tamilnadu, India
  • Madhukar Akkala Avanthi Institute of Pharmaceutical Sciences, JNTUH, Hyderabad, Telangana, India

DOI:

https://doi.org/10.22159/ijap.2018v10i6.28274

Keywords:

Floating drug delivery systems, Gastric retention, Mechanism, Single unit, Multiple units

Abstract

The principal objective behind the writing of this article on the floating drug delivery system (FDDS) was to systematize the recent literature with the core process of floatation in acquiring gastric retention. The different strategies used in the development of FDDS by constructing the effervescent and noneffervescent type of floating tablets basis of which is buoyancy mechanism. FDDS is a method to deliver the drugs that are active locally with a narrow absorption window in the upper gastrointestinal tract, unstable in the lower intestinal environment, and possess low solubility with higher pH values. The novel methodologies in FDDS include approaches to design a single unit and multiple-unit floating systems, the physiological and formulation variability affecting gastric retention along with the use of recently invented and developed polymers. This review also focuses on various in vitro techniques and in vivo studies in view of performance and application of floating systems. Floating dosage forms can be delivered in conventional forms like tablets, capsules with the addition of suitable ingredients along with the gas generating agent. This review also throws light on different techniques used in developing floating dosage forms along with current and novel advancements.

Downloads

Download data is not yet available.

References

Arora S, Ahuja A. Floating drug delivery system: a review. J AAPS PharmSciTech 2005;6:372–90.

Deshpande A, Rhodes C, Shah N, Malick A. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm 1996;22:631-9.

Hwang S, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carr Syst 1998;15:243-83.

Degen L, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, et al. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Gastroen 2001;120:361-8.

Kydoneius A. Controlled release technologies. 2nd Ed. New York: Marcel Dekker; 1991. p. 109.

Petrakis I, Kogerakis N, Vrachassotakis N, Stiakakis I, Zacharioudakis G, Chalkiadakis G. Hyperglycemia attenuate erythromycin-induced acceleration of solid phase gastric emptying in healthy subjects. Abd Imag 2002;27:309-14.

Silang R, Regalado M, Cheng T, Wesson D. Prokinetic agents increase plasma albumin in hypoalbuminemia chronic dialysis patients with delayed gastric emptying. J Kidney Dis 2001;37:287-93.

Garg S, Sharma S. Gastroretentive drug delivery system, Business Briefing: Pharmatech. 5th Edition; 2003. p. 160-6.

Singh, Chaudhary V. Preparation of eudragit E100 microspheres by a modified solvent evaporation method. Acta Pol Pharm 2011;68:975-80.

Meka L, Kesavan B, Chinnala K, Vobalaboina V, Yamsani M. Preparation of a matrix type multiple-unit gastro-retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation. AAPS Pharm Sci Tech 2008;9:612.

Hussein O, Mahmoud M, Azza A, Shereen H. Formulation of risperidone in floating microparticles to alleviate its extrapyramidal side effects. Fut J Pharm Sci 2016;2:43-59.

Zhang C, Xu M, Tao X, Tang J, Liu Z, Zhang Y, et al. A floating multiparticulate system for ofloxacin based on a multilayer structure: in vitro and in vivo evaluation. Int J Pharm 2012;430:141-50.

Shinde A, Waghule A, Paithane M, More H. Formulation and in vitro evaluation of sustained release floating tablet of cephalexin using hydrophilic polymers. Int J Pharm Pharm Sci 2010;2:58-65.

Hasnain M, Rishiwar P, Sadath A. Floating bioadhesive matrix tablets of hydralazine HCL made of cashew gum and HPMC K4M. Int J Pharm Pharm Sci 2017;9:124-9.

Manjunath P, Satish C, Vasanti S, Preetham A, Naidu R. Formulation and evaluation of the simvastatin gastro retentive drug delivery system. Int J Appl Pharm 2017;9:55-60.

Tekade B, Jadhao U, Patil S, Patil V. Formulation and in vitro evaluation of floating tablets of cefpodoxime proxetil. Int J Curr Pharm Res 2017;9:18-22.

Gunjal P, Shinde M, Gharge V, Pimple S, Gurjar M, Shah M. Design, development and optimization of s (-) Atenolol floating sustained release matrix tablets using surface response methodology. Ind J Pharm Sci 2015;77:563-72.

Agarwal S, Zamil F, Singh L, Saxena A. Formulation and evaluation of floating beads of Diltiazem HCl. Int J Curr Pharm Res 2016;8:38-42.

Chavda H, Patel C. Chitosan super porous hydrogel composite-based floating drug delivery system: a newer formulation approach. J Pharm Bioalli Sci 2010;2:124-31.

Durgapal S, Mukhopadhyay S, Goswami L. Preparation, characterization and evaluation of floating microparticles of ciprofloxacin. Int J Appl Pharm 2017;9:1-8.

Strubing S, Metz H, Mader K. Characterization of poly (vinyl acetate) based floating matrix tablets. J Controlled Release 2008;126:149-55.

Timmermans J, Moes A. How well floating dosage do forms float? Int J Pharm 1990;62:207-16.

Yang L, Fassihi R. Zero-order release kinetics from self-correcting floatable configuration drug delivery system. J Pharm Sci 1996;85:170-3.

Burns S, Attwood D, Barnwell SG. Assessment of a dissolution vessel designed for use with floating and erodible dosage forms. Int J Pharm 1998;160:213-8.

Joseph N, Laxmi S, Jayakrishnan A. A floating type oral dosage form for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J Controlled Release 2002;79:71-9.

Sheth P, Tossounian J. Sustained release pharmaceutical capsules. US patent 1978;4:126-672.

Soppimath K, Kulkarni A, Rudzinski W, Aminabhavi T. Microspheres as a floating drug delivery system to increase the gastric residence of drugs. Drug Metab Rev 2001;33:149-60.

Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: prepration and in vitro evaluation of floating and sustained-release kinetics. J Pharm Sci 1991;80:1062-6.

Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm Tech 2003;27:50-68.

Chandel A, Chauhan K, Parashar B, Kumar H, Arora S. Floating drug delivery systems: a better approach. Int Curr Pharm J 2012;1:110-8.

Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract. In: AJ Domb. (Ed.). Polymeric site-specific pharmacotherapy, Wiley, Chichester; 1994. p. 282-3.

Vyas SP, Roop KK. Controlled drug delivery concepts and advances. First Edition, New Delhi; 2002. p. 196-217.

Harshal S, Chetan G, Surbhi U, Sujit P. Development and in vitro evaluation of an oral floating tablet of metronidazole. J Drug Delivery Ther 2018;8:83-6.

Goyal M, Prajapati R, Purohit KK, Mehta SC. Floating drug delivery system. J Curr Pharm Res 2011;5:7-18.

Klausner E, Sara E, Lavy E, Friedman M, Hoffman A. Novel levodopa gastro-retentive dosage form: in vivo evaluation in dogs. J Controlled Release 2003;88:117-26.

Published

07-11-2018

How to Cite

Niharika, M. G., Krishnamoorthy, K., & Akkala, M. (2018). OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM. International Journal of Applied Pharmaceutics, 10(6), 65–71. https://doi.org/10.22159/ijap.2018v10i6.28274

Issue

Section

Review Article(s)